UNSPSC 51143711: Niacin/niacinamide/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN900. This VA Drug Class (CN900) classifies this compound as belonging to the group CNS MEDICATIONS, OTHER.

UNSPSC 51143711 Niacin/niacinamide/phenobarbital is a Commodity code that in practice covers a much broader range of pharmaceutical procurement than its nominal scope suggests—state and local governments are using it to solicit naloxone, drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. The issuing bodies span county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local participants including Oregon). Work solicited ranges from annual purchases of specific units (naloxone and deactivation systems with quarterly delivery schedules) to broad pharmaceutical supply agreements across hundreds of products with specified National Drug Codes, to exploratory requests for information on pharmacy benefit program restructuring and direct manufacturer contracting models.

Recent activity is geographically dispersed across Florida, Texas, Minnesota, and Oregon. Representative opportunities include Seminole County's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive-bid basis with quarterly deliveries; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescriptions program; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, evaluated at 75 percent on price competitiveness and requiring cGMP certification, DSCSA compliance, and $5,000,000 commercial general liability coverage with a contract term of two years. Set-asides and disadvantaged-enterprise restrictions do not appear in the available documentation for these opportunities.